Longevity PlusSemaglutide
Wegovy®, Ozempic®, Rybelsus®
Weight Loss Claim
Avg 15% at 12 months
Injected subcutaneously once weekly. Established cardiovascular benefits. Novo Nordisk offers significant self-pay savings programs for uninsured patients.
Tirzepatide
Zepbound®, Mounjaro®
Weight Loss Claim
Avg 21% at 12 months
Superior weight loss results compared to semaglutide. Dual-action targeting provides metabolic advantages. Often the preferred clinical choice at Xcelsior.
Retatrutide
Investigational
Weight Loss Claim
Up to 24% at 12 months
Triple-agonist targeting three receptors. Shows the highest average weight loss in clinical trials to date. Currently in Phase 3 trials.
Clinical Safety Profile
GI Tolerability and Discontinuation Data
| ADVERSE EVENT |
|---|
|
Nausea
|
|
Diarrhea
|
|
Vomiting
|
|
Constipation
|
|
Overall GI Events
|
|
Discontinuation Rate
|
| SEMAGLUTIDE 2.4MG |
|---|
|
44%
|
|
31%
|
|
25%
|
|
23%
|
|
57.5%
|
|
5.9-7.0%
|
| TIRZEPATIDE 5MG |
|---|
|
13-14%
|
|
12-21%
|
|
7-13%
|
|
NR
|
|
18.7-24.6%
|
|
6.0%
|
| RETATRUTIDE 1MG |
|---|
|
14%
|
|
Common (NR)
|
|
Common (NR)
|
|
Common (NR)
|
|
13%
|
|
7%
|
Xcelsior 3S Protocol
Strength, Structure Satiety
1. Resistance Training
- Minimum of 2 days per week
- Focus on compound movements
- Train close to muscular fatigue
- Walking alone is not enough to preserve muscle
2. Nutrition Targets
- Protein: ~0.7g per lb of goal body weight
- Daily fiber: 25–38g minimum
- Focus on establishing a consistent daily protein baseline
3. Food Quality
- Emphasize whole, minimally processed foods
- Prioritize lean proteins and vegetables at most meals
- Avoid liquid calories
- Limit ultra-processed snacks
4. Meal Timing
- Eat 2–3 structured meals per day
- Plan meals in advance
- Avoid grazing and continuous snacking between meals
5. Objective Data
- Baseline SECA analysis required
- Repeat SECA within 1 year
- Ongoing labs (CMP, A1c, fasting insulin) every 6–12 months
Total caloric intake should be discussed individually with your provider.
Insurance Requirements:
Obesity Indication:
- BMI 30 or higher (Obesity)
- BMI 27-29 + Comorbidity (Heart Disease, Sleep Apnea, etc.)
- Branded Wegovy or Zepbound Focus
Diabetes Indication:
- Type 2 Diabetes Diagnosis
- Prior Trial and Failure of Metformin
- Branded Ozempic or Mounjaro Focus
Standard List Pricing (Retail)
Semaglutide
Commercial monthly list price
~$1,300
Tirzepatide
Commercial monthly list price
~$1,000
Retatrutide
Commercial monthly list price
N/A
Wegovy Manufacturer Savings Options
$199 per month
New self-pay/uninsured patients (First 0.25mg and 0.5mg doses)
$349 per month
New self-pay/uninsured patients (First 0.25mg and 0.5mg doses)
Xcelsior Health prioritizes FDA-approved manufacturer savings programs over compounded alternatives.
Maximizing Your Investment
By utilizing a high-dose 15 mg vial (priced at $450) and following a low-dose 2.5 mg weekly schedule, your medication duration can be extended up to 16 weeks.